These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 8336071

  • 21. Effect of combined adoptive immunotherapy and radiotherapy on tumor growth.
    Sumareva R, Ukrainsky G, Kiremidjian-Schumacher L, Roy M, Wishe HI, Steinfeld AD, Cooper JS.
    Radiat Oncol Investig; 1999; 7(1):22-9. PubMed ID: 10030620
    [Abstract] [Full Text] [Related]

  • 22. Editorial: Osteosarcoma.
    Enneking WF.
    Clin Orthop Relat Res; 1975 Sep; (111):2-4. PubMed ID: 1057463
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Problems in the interpretation of results of treatment for osteosarcoma.
    Dahlin DC.
    Mayo Clin Proc; 1979 Sep; 54(9):621-2. PubMed ID: 288961
    [No Abstract] [Full Text] [Related]

  • 25. Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins.
    Zanovello P, Rosato A, Bronte V, Cerundolo V, Collavo D.
    Ann Ist Super Sanita; 1991 Sep; 27(1):91-5. PubMed ID: 1958033
    [Abstract] [Full Text] [Related]

  • 26. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 Sep; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC, Belldegrun A, Figlin RA.
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
    Gautam SC, Chikkala NF, Lewis I, Grabowski DR, Finke JH, Ganapathi R.
    Anticancer Res; 1992 Feb; 12(3):921-5. PubMed ID: 1622150
    [Abstract] [Full Text] [Related]

  • 33. Discordant effects of activator protein-1 transcription factor on gene regulation, invasion, and metastasis in spontaneous, radiation-induced, and fos-induced osteosarcomas.
    Rupp B, Lorenz U, Schmidt J, Werenskiold AK.
    Mol Carcinog; 1998 Oct; 23(2):69-75. PubMed ID: 9808160
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Lymphokine-activated killer lymphocytes: biotherapeutics clinical trials.
    West WH.
    Immunol Ser; 1989 Oct; 48():79-92. PubMed ID: 2488327
    [No Abstract] [Full Text] [Related]

  • 36. [Cellular immunotherapy for malignant glioma].
    Okamoto Y, Yamashita J.
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
    [No Abstract] [Full Text] [Related]

  • 37. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
    Duan DS.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993 Sep; 28(5):281-3, 314. PubMed ID: 8192930
    [Abstract] [Full Text] [Related]

  • 38. [Adoptive immunotherapy with interleukin-2 and with interleukin-2 activated lymphocytes].
    Eggermont AM, Stoter G, Jansen RL, Bolhuis RL.
    Ned Tijdschr Geneeskd; 1989 Jul 15; 133(28):1387-92. PubMed ID: 2677757
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.